Clinical trials: Neoplasm, Oral
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia
This is a phase I/II pediatric dose-ranging study that will evaluate the safety, tolerability, clinical response, pharmacokinetics and pharmacodynamics of midostaurin in patients <18 years of age who have relapsed or refractory…
- Trial name
- NCT00866281
- Testing
- midostaurin
- Where
- 8 sites in United States, France and 3 more
- Volunteers
- 22 people
- Sponsor
- Novartis Pharmaceuticals
Head and Neck Cancer
Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00423930
- Testing
- bevacizumab, cisplatin, conventional surgery
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukoplakia, Oral, Benign Neoplasms
A Randomized Study of Sulindac in Oral Premalignant Lesions
The purpose of this study is to see if a drug called sulindac can prevent the development of changes in the mouth that are related to oral pre-cancer growths (oral epithelial dysplasia) or oral cancer.
- Trial name
- NCT00299195
- Testing
- sulindac
- Where
- 3 sites in United States, India
- Volunteers
- 63 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pain, Neoplasms
CORAL XT - Open-label Extension Trial of the CORAL Trial
The purpose of this trial was to find out how well cebranopadol is tolerated and how often, and which, adverse reactions occur when it is taken every day for a longer period of time.
- Conditions
- Pain, Neoplasms, Chronic Pain
- Trial name
- CORAL XT (NCT02031432)
- Testing
- Cebranopadol
- Where
- 22 sites in Austria, Belgium and 8 more
- Volunteers
- 76 people
- Sponsor
- Tris Pharma, Inc.
Multiple Myeloma, Advanced Solid Tumors
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment
The purpose of this study is to characterize the single-dose pharmacokinetic (PK) parameters of ixazomib (MLN9708) in cancer participants with either normal renal function or severe renal impairment (RI), including participants…
- Trial name
- NCT01830816
- Testing
- Ixazomib
- Where
- 11 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Lung Cancer, Non-Small Cell
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
The current prognosis for patients with metastatic brain cancer from NSCLC is very poor. The current standard treatment for this disease is radiation therapy to the brain.
- Trial name
- NCT00390806
- Testing
- HYCAMTIN, oral capsules, Radiation
- Where
- 88 sites in United States, Canada and 4 more
- Volunteers
- 472 people
- Sponsor
- GlaxoSmithKline
Carcinoma, Non-Small-Cell Lung
Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy
To determine the appropriateness of the dose of nintedanib 200 mg b.i.d. plus docetaxel 75 mg/m2 as starting dose by evaluating the safety in Japanese patients with body surface area (BSA) <1.5 m2 and locally advanced or…
- Trial name
- NCT02300298
- Testing
- Nintedanib, Docetaxel
- Where
- 6 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Boehringer Ingelheim
Advanced Solid Tumors, Non-small Cell Lung Cancer
Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer
This is the first human study to use X-396 (ensartinib), a drug being developed for treatment of advanced cancers. The initial purpose of the study is to determine the largest amount of X-396 that can be safely given to humans…
- Trial name
- NCT01625234
- Testing
- Phase I: X-396 (ensartinib), Phase II: X-396 (ensartinib)
- Where
- 14 sites in United States
- Volunteers
- 131 people
- Sponsor
- Xcovery Holdings, Inc.
Malignant Head and Neck Neoplasm, Mucositis
Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy
This randomized phase III trial studies how well gabapentin plus standard of care work compares to standard of care without Gabapentin in preventing inflammation of the mucous membranes (mucositis) in patients with stage III-IV…
- Conditions
- Malignant Head and Neck Neoplasm, Mucositis, Radiation-Induced Disorder
- Trial name
- NCT02480114
- Testing
- Educational Intervention, Gabapentin, Pain Therapy
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Uterine Fibroids
A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids
The purpose of this study is to evaluate the efficacy of Relugolix (TAK-385) 40 mg administered orally once daily for 12 weeks, compared with leuprorelin injection (once every 4 weeks, 1.88 mg or 3.75 mg subcutaneously [SC]/time)…
- Trial name
- NCT02655237
- Testing
- Relugolix, Leuprorelin
- Where
- 25 sites in Japan
- Volunteers
- 281 people
- Sponsor
- Takeda
Head Cancer, Neck Cancer
Transcutaneous Electrical Nerve Stimulation (TENS) and Head and Neck Cancer Pain (HNC) (TENS & HNC)
The overall goal of this study is to examine the effect of a single dose of TENS on mucositis pain and function secondary to head and neck radiation therapies.
- Conditions
- Head Cancer, Neck Cancer, Pain
- Trial name
- NCT01194466
- Testing
- Transcutaneous Electrical Nerve Stimulation (TENS)
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Jennifer E. Lee
Recurrent Oral Cavity Adenoid Cystic Carcinoma, Recurrent Salivary Gland Carcinoma
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
This phase II trial studies how well Akt inhibitor MK2206 works in treating patients with progressive, recurrent, or metastatic adenoid cyst carcinoma (cancer).
- Conditions
- Recurrent Oral Cavity Adenoid Cystic Carcinoma, Recurrent Salivary Gland Carcinoma, Salivary Gland Adenoid Cystic Carcinoma, Stage IVA Major Salivary Gland Cancer AJCC v7
- Trial name
- NCT01604772
- Testing
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis
- Where
- 51 sites in United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Adenomatous Polyp, Colorectal Carcinoma
Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer
This randomized phase II trial studies how well macrogol 3350-based oral osmotic laxative (polyethylene glycol 3350) works in preventing cancer in patients at risk of colorectal cancer.
- Trial name
- NCT00828984
- Testing
- macrogol 3350-based oral osmotic laxative, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 87 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoid, Lymphoma, Non-Hodgkin
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
A study of the safety, side effects, and effectiveness of LOXO-305 in Chinese adults with lymphoma or chronic leukemia who have already had standard of care treatment. Participation could last up to four years.
- Conditions
- Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse
- Trial name
- NCT04849416
- Testing
- LOXO-305
- Where
- 22 sites in China
- Volunteers
- 87 people
- Sponsor
- Eli Lilly and Company
Head and Neck Cancer, Cancer of the Pharynx
Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer
For advanced head and neck cancer, combined radiation and chemotherapy prevents recurrences and for many patients, improves survival.
- Conditions
- Head and Neck Cancer, Cancer of the Pharynx, Cancer of the Larynx, Nose Neoplasms
- Trial name
- NCT00462735
- Testing
- Cetuximab, Hydroxyurea, Fluorouracil
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Johnny Kao
Chronic Myelogenous Leukemia
Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
The purpose of the study is to optimize the treatment of asciminib in patients with chronic myelogenous leukemia in chronic phase (CML-CP) previously treated with 2 or more Tyrosine Kinase Inhibitors (TKIs).
- Trial name
- NCT04948333
- Testing
- ABL001 40mg BID, ABL001 80mg QD, ABL001 200mg QD
- Where
- 48 sites in Argentina, Austria and 14 more
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Glioblastoma
Bosutinib in Adult Patients With Recurrent Glioblastoma
For many brain tumors, one reason that chemotherapy drugs might not be effective is that the drug may not be able to get into the brain tumor and kill the cancer cells.
- Trial name
- NCT01331291
- Testing
- bosutinib
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Massachusetts General Hospital
Parotid Neoplasm, Thyroid Neoplasms
Bevonescein to Highlight Nerves in Patients Undergoing Head & Neck Surgery
Bevonescein to Highlight Nerves in Patients Undergoing Head \& Neck Surgery
- Conditions
- Parotid Neoplasm, Thyroid Neoplasms, Head and Neck Neoplasms, Surgery
- Trial name
- NCT04420689
- Testing
- Bevonescein
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Alume Biosciences, Inc.
Gastrointestinal Stromal Tumors (GIST), Neoplasms, Connective Tissue
A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
This study will assess the safety, efficacy, and pharmacokinetics of THE-630 in participants with advanced gastrointestinal stromal tumors (GIST).
- Conditions
- Gastrointestinal Stromal Tumors (GIST), Neoplasms, Connective Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type
- Trial name
- NCT05160168
- Testing
- THE-630
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Theseus Pharmaceuticals
Cancer
A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer
This study will determine the maximum tolerated dose of oral ixabepilone administered for 5 successive days every 21 days in participants with advanced cancer.
- Trial name
- NCT00422097
- Testing
- Ixabepilone, 5 mg/d, Ixabepilone, 10 mg/d, Ixabepilone, 15 mg/d
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- R-Pharm